Arrestin3 mediates D(2) dopamine receptor internalization.
Skinbjerg
Mette
M
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.
Ariano
Marjorie A
MA
Thorsell
Annika
A
Heilig
Markus
M
Halldin
Christer
C
Innis
Robert B
RB
Sibley
David R
DR
D000818:Animals; D019390:Arrestins / Q000378:metabolism*; D001552:Benzazepines / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008856:Microscopy, Fluorescence; D009288:Naproxen / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012457:Salicylamides / Q000494:pharmacology
D019390:Arrestins; D001552:Benzazepines; D015259:Dopamine Agents; D017448:Receptors, Dopamine D2; D012457:Salicylamides; C082333:arrestin3; D009288:Naproxen; C067113:SK&F 81297; C045989:eticlopride; D004298:Dopamine